Obesity Drugs' CV Risk Assessment Needs Hard End Points

"That makes perfect sense to me. I’ll go along with that," said Dr. Michael A. Proschan of the National Institute of Allergy and Infectious Diseases in Bethesda, Md. That "sounds like a reasonable idea," Erica Brittain, Ph.D., also of NIAID, agreed.

Cathy Dombrowski is with "The Pink Sheet." Both this news organization and "The Pink Sheet" are owned by Elsevier.